BlackRock Amends Karyopharm Stake, Maintains Passive Position
Ticker: KPTI · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a chunk of Karyopharm, but it's a passive investment.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Karyopharm Therapeutics Inc. common stock as of December 31, 2023. This filing, an amendment to a previous one, shows BlackRock's continued significant, though passive, stake in Karyopharm. For investors, this means a major institutional investor maintains confidence in Karyopharm, which can be a positive signal, but it doesn't suggest any active involvement in the company's management or strategy.
Why It Matters
This filing confirms BlackRock's ongoing, substantial investment in Karyopharm, signaling institutional confidence without indicating any intent to influence company operations.
Risk Assessment
Risk Level: low — This filing is routine and indicates a passive investment by a large institution, posing minimal direct risk to Karyopharm shareholders.
Analyst Insight
An investor should note that BlackRock's continued passive ownership is a sign of institutional presence but does not imply any upcoming strategic changes or activist involvement from BlackRock. Further research into Karyopharm's fundamentals and recent news would be more impactful than this routine filing.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Karyopharm Therapeutics Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A amendment
- 48576U106 (other) — the CUSIP number for Karyopharm Therapeutics Inc. Common Stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing under the Securities Exchange Act of 1934, specifically Amendment No. 2.
Who is the 'reporting person' in this filing?
The reporting person is BlackRock, Inc., as stated in item (1) of the cover page.
What is the 'subject company' or 'issuer' of the securities?
The subject company, or issuer, is Karyopharm Therapeutics Inc., as identified in the filing.
What is the CUSIP number for the securities reported?
The CUSIP number for the Common Stock of Karyopharm Therapeutics Inc. is 48576U106.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Karyopharm Therapeutics Inc. (KPTI).